## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.5% below STRENGTH zone (4.0-10.0%); PEG 2.13 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (53% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($132.21)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. AGILENT TECHNOLOGIES, INC. SEC 10-K Report**
- Source: TradingView â€” Track All Markets | 20251222T110749 | Neutral | Relevance: 100%
- Agilent Technologies, Inc. has released its 2025 10-K report, highlighting a 7% increase in total net revenue to $6,948 million, despite a decrease in gross and operating margins. The company restructured into three segments: Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets, to enhance operational efficiency and customer focus. Strategic initiatives include a restructuring plan to reduce costs, a new share repurchase program, and ongoing investments in R&D, while facing challenges from global operations, economic instability, and regulatory changes.

**2. Agilent Technologies opens India refurbishment center to promote sustainable science**
- Source: FoodTechBiz | 20251222T050759 | Bullish | Relevance: 100%
- Agilent Technologies has inaugurated its India Refurbishment Center and India Education Center in Manesar, Haryana, to promote sustainable science and affordability. The facility will provide Certified Pre-Owned instruments and hands-on training, reinforcing Agilent's commitment to the Indian market. This initiative aims to support laboratories with cost-effective solutions and empower customers with advanced tools while adhering to environmentally responsible practices.

**3. Osaic Holdings Inc. Has $8.02 Million Stock Position in Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251222T110354 | Somewhat-Bullish | Relevance: 100%
- Osaic Holdings Inc. significantly increased its stake in Agilent Technologies, Inc. during the second quarter, now holding 68,053 shares valued at $8.02 million. This comes as Agilent reported strong quarterly earnings, beat analyst expectations, and raised its dividend, signaling positive financial health. Despite institutional buying, company insiders have recently been net sellers, disposing of over $2.4 million worth of stock.

**4. 7 DE Admin. Code 1102 Natural Minor Permit Applications: Agilent Technologies, Inc.**
- Source: Delaware.gov | 20251224T090805 | Neutral | Relevance: 100%
- Agilent Technologies, Inc. has applied for a Natural Minor permit to install three electric burn-off ovens with associated reduction units and adsorptions converters at their Wilmington facility. This equipment is permitted to emit specific amounts of VOCs, Formaldehyde, Methanol, Ammonia, and Acetone. The public has until January 8, 2026, to comment or request a public hearing on the application.

**5. Voya Investment Management LLC Cuts Stake in Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251223T134039 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC reduced its stake in Agilent Technologies (NYSE:A) by 15.2% in Q3, selling 17,718 shares and retaining 98,991 shares valued at $12.7 million. Despite this, Agilent reported strong quarterly results, beating EPS and revenue estimates, and brokerages have maintained a "Moderate Buy" rating with an average target price of $161.77. The company also announced an increase in its quarterly dividend to $0.255.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $165 | $165 | 0% |
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | up | Overweight |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.13 elevated, pricing in significant growth expectations. Forward P/E 21.1x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.2B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.13 |
| Forward P/E | 21.1 |
| Current P/E | 23.2 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -5.6% to -4.5% (+1.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 8.5pp (needs >4.0% for momentum thesis). AM_20 at -3.5% indicates price below own 20MA trend. Underperforming sector by 4.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-0.63), momentum weakening. Volume at 53% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.54% (CS: 12) | Weak |
| RSI_14 | 39.3 | Neutral |
| MACD Histogram | -0.63 | Bearish |
| vs SMA20 | 0.965x | Below |
| vs SMA50 | 0.953x | Below |
| vs SMA200 | 1.109x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $138.23
- **Stop Loss:** $132.21 (4.4% risk)
- **Target:** $144.25 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 199
- **Position Value:** $27,507.77
- **Portfolio %:** 27.51%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*